Axogen
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Axogen and other ETFs, options, and stocks.About AXGN
Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity.
CEOMichael D. Dale
CEOMichael D. Dale
Employees452
Employees452
HeadquartersAlachua, Florida
HeadquartersAlachua, Florida
Founded1977
Founded1977
Employees452
Employees452
AXGN Key Statistics
Market cap1.47B
Market cap1.47B
Price-Earnings ratio-652.65
Price-Earnings ratio-652.65
Dividend yield—
Dividend yield—
Average volume979.11K
Average volume979.11K
High today$32.57
High today$32.57
Low today$31.06
Low today$31.06
Open price$31.53
Open price$31.53
Volume835.82K
Volume835.82K
52 Week high$34.24
52 Week high$34.24
52 Week low$9.22
52 Week low$9.22
Stock Snapshot
Axogen(AXGN) stock is priced at $31.68, giving the company a market capitalization of 1.47B. It carries a P/E multiple of -652.65.
On 2025-12-19, Axogen(AXGN) stock moved within a range of $31.06 to $32.57. With shares now at $31.68, the stock is trading +2.0% above its intraday low and -2.7% below the session's peak.
Trading activity shows a volume of 835.82K, compared to an average daily volume of 979.11K.
The stock's 52-week range extends from a low of $9.22 to a high of $34.24.
The stock's 52-week range extends from a low of $9.22 to a high of $34.24.
AXGN News
Simply Wall St 5d
Should FDA Biologic Approval of AVANCE Nerve Scaffold Require Action From Axogen Investors?Axogen, Inc. recently announced that the U.S. FDA has approved its Biologics License Application for AVANCE, an acellular nerve scaffold indicated for treating...
Analyst ratings
100%
of 10 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own AXGN. This list is generated using Robinhood data, and it’s not a recommendation.